Psoriasis Drug Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Class; By Type (Psoriatic Arthritis, Plaque Psoriasis, Other); By Treatment Type (Topical, Systematic, Biologics); By Region; Segment Forecast, 2024 - 2032
Description
The psoriasis drug market size is expected to reach USD 56.96 billion by 2034, according to a new study by Polaris Market Research. The report “Psoriasis Drug Market Size, Share, Trends, Industry Analysis Report: By Class (Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Vitamin D Analogues, Corticosteriods, and Others), Type, Treatment, Route of Administration, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The psoriasis drug market demand is driven by the rising prevalence of psoriasis, growing awareness of advanced treatment options, and increasing adoption of biologics and targeted therapies. Key opportunities lie in the development of biosimilars and innovative drug delivery systems, addressing the unmet needs of underserved patient populations, particularly in emerging markets.
Psoriasis drug market trends such as the shift toward personalized medicine, advancements in digital health integration, and combination therapies are shaping the market landscape. Continuous research and regulatory approvals for novel therapies are propelling innovation and expanding treatment options, contributing to the market growth and evolution.
Psoriasis Drug Market Report Highlights
Based on class, the interleukin inhibitors segment dominates the psoriasis drug market share due to their high efficacy and safety in managing moderate-to-severe psoriasis, while ongoing innovations drive their rapid growth.
The biologics segment, by treatment, holds the largest share and is the fastest-growing segment, driven by their targeted approach and widespread adoption for severe psoriasis cases.
By route of administration, the parenteral segment leads the psoriasis drug market revenue share, supported by the growing use of injectable biologics, which also exhibit the highest growth due to improved delivery technologies.
The hospital pharmacies segment, by distribution channel, dominates the market, benefiting from their role in dispensing biologics, while their growth is driven by the increasing prevalence of severe cases requiring specialized care.
North America dominates the psoriasis drug market share due to advanced healthcare infrastructure and high adoption of biologics. However, Asia Pacific is the fastest-growing region, driven by increasing healthcare investments and expanding access to advanced therapies.
Polaris Market Research has segmented the psoriasis drug market report on the basis of class, type, treatment, route of administration, distribution channel, and region:
By Class Outlook (Revenue – USD Billion, 2020–2034)
Tumor Necrosis Factor Inhibitors
Interleukin Inhibitors
Vitamin D Analogues
Corticosteriods
Others
By Type (Revenue – USD Billion, 2020–2034)
Psoriatic Arthritis
Plaque Psoriasis
Others
By Treatment Outlook (Revenue – USD Billion, 2020–2034)
Topicals
Systemic
Biologics
By Route of Administration Outlook (Revenue – USD Billion, 2020–2034)
Oral
Parenteral
Topical
By Distribution Channel Outlook (Revenue – USD Billion, 2020–2034)
Hospital Pharmacies
Retail Pharmacies
Others
By Regional Outlook (Revenue – USD Billion, 2020–2034)
North America
The psoriasis drug market demand is driven by the rising prevalence of psoriasis, growing awareness of advanced treatment options, and increasing adoption of biologics and targeted therapies. Key opportunities lie in the development of biosimilars and innovative drug delivery systems, addressing the unmet needs of underserved patient populations, particularly in emerging markets.
Psoriasis drug market trends such as the shift toward personalized medicine, advancements in digital health integration, and combination therapies are shaping the market landscape. Continuous research and regulatory approvals for novel therapies are propelling innovation and expanding treatment options, contributing to the market growth and evolution.
Psoriasis Drug Market Report Highlights
Based on class, the interleukin inhibitors segment dominates the psoriasis drug market share due to their high efficacy and safety in managing moderate-to-severe psoriasis, while ongoing innovations drive their rapid growth.
The biologics segment, by treatment, holds the largest share and is the fastest-growing segment, driven by their targeted approach and widespread adoption for severe psoriasis cases.
By route of administration, the parenteral segment leads the psoriasis drug market revenue share, supported by the growing use of injectable biologics, which also exhibit the highest growth due to improved delivery technologies.
The hospital pharmacies segment, by distribution channel, dominates the market, benefiting from their role in dispensing biologics, while their growth is driven by the increasing prevalence of severe cases requiring specialized care.
North America dominates the psoriasis drug market share due to advanced healthcare infrastructure and high adoption of biologics. However, Asia Pacific is the fastest-growing region, driven by increasing healthcare investments and expanding access to advanced therapies.
Polaris Market Research has segmented the psoriasis drug market report on the basis of class, type, treatment, route of administration, distribution channel, and region:
By Class Outlook (Revenue – USD Billion, 2020–2034)
Tumor Necrosis Factor Inhibitors
Interleukin Inhibitors
Vitamin D Analogues
Corticosteriods
Others
By Type (Revenue – USD Billion, 2020–2034)
Psoriatic Arthritis
Plaque Psoriasis
Others
By Treatment Outlook (Revenue – USD Billion, 2020–2034)
Topicals
Systemic
Biologics
By Route of Administration Outlook (Revenue – USD Billion, 2020–2034)
Oral
Parenteral
Topical
By Distribution Channel Outlook (Revenue – USD Billion, 2020–2034)
Hospital Pharmacies
Retail Pharmacies
Others
By Regional Outlook (Revenue – USD Billion, 2020–2034)
North America
- US
- Canada
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
119 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. Global Psoriasis Drug Market Insights
- 4.1. Psoriasis Drug Market – Frequency Snapshot
- 4.2. Psoriasis Drug Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Prevalence of Psoriasis Globally
- 4.2.1.2. Advancements in Biologic and Biosimilar Therapies
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Cost of Biologics and Targeted Therapies
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Psoriasis Drug Market Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. Global Psoriasis Drug Market, by Class
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 5.3. Tumor Necrosis Factor Inhibitors
- 5.3.1. Global Psoriasis Drug Market, by Tumor Necrosis Factor Inhibitors, by Region, 2020–2034 (USD Billion)
- 5.4. Interleukin Inhibitors
- 5.4.1. Global Psoriasis Drug Market, by Interleukin Inhibitors, by Region, 2020–2034 (USD Billion)
- 5.5. Vitamin D Analogues
- 5.5.1. Global Psoriasis Drug Market, by Vitamin D Analogues, by Region, 2020–2034 (USD Billion)
- 5.6. Corticosteriods
- 5.6.1. Global Psoriasis Drug Market, by Corticosteriods, by Region, 2020–2034 (USD Billion)
- 5.7. Others
- 5.7.1. Global Psoriasis Drug Market, by Others, by Region, 2020–2034 (USD Billion)
- 6. Global Psoriasis Drug Market, by Type
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 6.3. Psoriatic Arthritis
- 6.3.1. Global Psoriasis Drug Market, by Psoriatic Arthritis, by Region, 2020–2034 (USD Billion)
- 6.4. Plaque Psoriasis
- 6.4.1. Global Psoriasis Drug Market, by Plaque Psoriasis, by Region, 2020–2034 (USD Billion)
- 6.5. Others
- 6.5.1. Global Psoriasis Drug Market, by Others, by Region, 2020–2034 (USD Billion)
- 7. Global Psoriasis Drug Market, by Treatment
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 7.3. Topicals
- 7.3.1. Global Psoriasis Drug Market, by Topicals, by Region, 2020–2034 (USD Billion)
- 7.4. Systemic
- 7.4.1. Global Psoriasis Drug Market, by Systemic, by Region, 2020–2034 (USD Billion)
- 7.5. Biologics
- 7.5.1. Global Psoriasis Drug Market, by Biologics, by Region, 2020–2034 (USD Billion)
- 8. Global Psoriasis Drug Market, by Route of Administration
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.3. Oral
- 8.3.1. Global Psoriasis Drug Market, by Oral, by Region, 2020–2034 (USD Billion)
- 8.4. Parenteral
- 8.4.1. Global Psoriasis Drug Market, by Parenteral, by Region, 2020–2034 (USD Billion)
- 8.5. Topical
- 8.5.1. Global Psoriasis Drug Market, by Topical, by Region, 2020–2034 (USD Billion)
- 9. Global Psoriasis Drug Market, by Distribution Channel
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Global Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 9.3. Hospital Pharmacies
- 9.3.1. Global Psoriasis Drug Market, by Hospital Pharmacies, by Region, 2020–2034 (USD Billion)
- 9.4. Retail Pharmacies
- 9.4.1. Global Psoriasis Drug Market, by Retail Pharmacies, by Region, 2020–2034 (USD Billion)
- 9.5. Others
- 9.5.1. Global Psoriasis Drug Market, by Others, by Region, 2020–2034 (USD Billion)
- 10. Global Psoriasis Drug Market, by Geography
- 10.1. Key Findings
- 10.2. Introduction
- 10.2.1. Psoriasis Drug Market Assessment, By Geography, 2020–2034 (USD Billion)
- 10.3. Psoriasis Drug Market – North America
- 10.3.1. North America: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.3.2. North America: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.3.3. North America: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.3.4. North America: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.3.5. North America: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.3.6. Psoriasis Drug Market – US
- 10.3.6.1. U.S.: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.3.6.2. U.S.: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.3.6.3. U.S.: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.3.6.4. U.S.: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.3.6.5. U.S.: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.3.7. Psoriasis Drug Market – Canada
- 10.3.7.1. Canada: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.3.7.2. Canada: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.3.7.3. Canada: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.3.7.4. Canada: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.3.7.5. Canada: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.4. Psoriasis Drug Market – Europe
- 10.4.1. Europe: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.4.2. Europe: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.4.3. Europe: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.4.4. Europe: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.4.5. Europe: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.4.6. Psoriasis Drug Market – UK
- 10.4.6.1. UK: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.4.6.2. UK: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.4.6.3. UK: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.4.6.4. UK: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.4.6.5. UK: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.4.7. Psoriasis Drug Market – France
- 10.4.7.1. France: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.4.7.2. France: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.4.7.3. France: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.4.7.4. France: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.4.7.5. France: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.4.8. Psoriasis Drug Market – Germany
- 10.4.8.1. Germany: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.4.8.2. Germany: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.4.8.3. Germany: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.4.8.4. Germany: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.4.8.5. Germany: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.4.9. Psoriasis Drug Market – Italy
- 10.4.9.1. Italy: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.4.9.2. Italy: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.4.9.3. Italy: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.4.9.4. Italy: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.4.9.5. Italy: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.4.10. Psoriasis Drug Market – Spain
- 10.4.10.1. Spain: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.4.10.2. Spain: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.4.10.3. Spain: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.4.10.4. Spain: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.4.10.5. Spain: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.4.11. Psoriasis Drug Market – Netherlands
- 10.4.11.1. Netherlands: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.4.11.2. Netherlands: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.4.11.3. Netherlands: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.4.11.4. Netherlands: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.4.11.5. Netherlands: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.4.12. Psoriasis Drug Market – Russia
- 10.4.12.1. Russia: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.4.12.2. Russia: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.4.12.3. Russia: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.4.12.4. Russia: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.4.12.5. Russia: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.4.13. Psoriasis Drug Market – Rest of Europe
- 10.4.13.1. Rest of Europe: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.4.13.2. Rest of Europe: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.4.13.3. Rest of Europe: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.4.13.4. Rest of Europe: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.4.13.5. Rest of Europe: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.5. Psoriasis Drug Market – Asia Pacific
- 10.5.1. Asia Pacific: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.5.2. Asia Pacific: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.5.3. Asia Pacific: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.5.4. Asia Pacific: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.5.5. Asia Pacific: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.5.6. Psoriasis Drug Market – China
- 10.5.6.1. China: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.5.6.2. China: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.5.6.3. China: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.5.6.4. China: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.5.6.5. China: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.5.7. Psoriasis Drug Market – India
- 10.5.7.1. India: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.5.7.2. India: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.5.7.3. India: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.5.7.4. India: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.5.7.5. India: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.5.8. Psoriasis Drug Market – Malaysia
- 10.5.8.1. Malaysia: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.5.8.2. Malaysia: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.5.8.3. Malaysia: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.5.8.4. Malaysia: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.5.8.5. Malaysia: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.5.9. Psoriasis Drug Market – Japan
- 10.5.9.1. Japan: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.5.9.2. Japan: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.5.9.3. Japan: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.5.9.4. Japan: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.5.9.5. Japan: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.5.10. Psoriasis Drug Market – Indonesia
- 10.5.10.1. Indonesia: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.5.10.2. Indonesia: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.5.10.3. Indonesia: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.5.10.4. Indonesia: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.5.10.5. Indonesia: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.5.11. Psoriasis Drug Market – South Korea
- 10.5.11.1. South Korea: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.5.11.2. South Korea: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.5.11.3. South Korea: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.5.11.4. South Korea: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.5.11.5. South Korea: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.5.12. Psoriasis Drug Market – Australia
- 10.5.12.1. Australia: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.5.12.2. Australia: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.5.12.3. Australia: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.5.12.4. Australia: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.5.12.5. Australia: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.5.13. Psoriasis Drug Market – Rest of Asia Pacific
- 10.5.13.1. Rest of Asia Pacific: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.5.13.2. Rest of Asia Pacific: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.5.13.3. Rest of Asia Pacific: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.5.13.4. Rest of Asia Pacific: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.5.13.5. Rest of Asia Pacific: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.6. Psoriasis Drug Market – Middle East & Africa
- 10.6.1. Middle East & Africa: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.6.2. Middle East & Africa: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.6.3. Middle East & Africa: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.6.4. Middle East & Africa: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.6.5. Middle East & Africa: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.6.6. Psoriasis Drug Market – Saudi Arabia
- 10.6.6.1. Saudi Arabia: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.6.6.2. Saudi Arabia: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.6.6.3. Saudi Arabia: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.6.6.4. Saudi Arabia: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.6.6.5. Saudi Arabia: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.6.7. Psoriasis Drug Market – UAE
- 10.6.7.1. UAE: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.6.7.2. UAE: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.6.7.3. UAE: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.6.7.4. UAE: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.6.7.5. UAE: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.6.8. Psoriasis Drug Market – Israel
- 10.6.8.1. Israel: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.6.8.2. Israel: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.6.8.3. Israel: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.6.8.4. Israel: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.6.8.5. Israel: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.6.9. Psoriasis Drug Market – South Africa
- 10.6.9.1. South Africa: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.6.9.2. South Africa: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.6.9.3. South Africa: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.6.9.4. South Africa: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.6.9.5. South Africa: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.6.10. Psoriasis Drug Market – Rest of Middle East & Africa
- 10.6.10.1. Rest of Middle East & Africa: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.6.10.2. Rest of Middle East & Africa: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.6.10.3. Rest of Middle East & Africa: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.6.10.4. Rest of Middle East & Africa: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.6.10.5. Rest of Middle East & Africa: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.7. Psoriasis Drug Market – Latin America
- 10.7.1. Latin America: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.7.2. Latin America: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.7.3. Latin America: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.7.4. Latin America: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.7.5. Latin America: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.7.6. Psoriasis Drug Market – Mexico
- 10.7.6.1. Mexico: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.7.6.2. Mexico: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.7.6.3. Mexico: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.7.6.4. Mexico: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.7.6.5. Mexico: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.7.7. Psoriasis Drug Market – Brazil
- 10.7.7.1. Brazil: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.7.7.2. Brazil: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.7.7.3. Brazil: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.7.7.4. Brazil: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.7.7.5. Brazil: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.7.8. Psoriasis Drug Market – Argentina
- 10.7.8.1. Argentina: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.7.8.2. Argentina: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.7.8.3. Argentina: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.7.8.4. Argentina: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.7.8.5. Argentina: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 10.7.9. Psoriasis Drug Market – Rest of Latin America
- 10.7.9.1. Rest of Latin America: Psoriasis Drug Market, by Class, 2020–2034 (USD Billion)
- 10.7.9.2. Rest of Latin America: Psoriasis Drug Market, by Type, 2020–2034 (USD Billion)
- 10.7.9.3. Rest of Latin America: Psoriasis Drug Market, by Treatment, 2020–2034 (USD Billion)
- 10.7.9.4. Rest of Latin America: Psoriasis Drug Market, by Route of Administration, 2020–2034 (USD Billion)
- 10.7.9.5. Rest of Latin America: Psoriasis Drug Market, by Distribution Channel, 2020–2034 (USD Billion)
- 11. Competitive Landscape
- 11.1. Expansion and Acquisition Analysis
- 11.1.1. Expansion
- 11.1.2. Acquisitions
- 11.2. Partnerships/Collaborations/Agreements/Exhibitions
- 12. Company Profiles
- 12.1. AbbVie Inc.
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Benchmarking
- 12.1.4. Recent Development
- 12.2. Amgen Inc.
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Benchmarking
- 12.2.4. Recent Development
- 12.3. Johnson & Johnson Services, Inc.
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Benchmarking
- 12.3.4. Recent Development
- 12.4. Novartis AG
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Benchmarking
- 12.4.4. Recent Development
- 12.5. Eli Lilly and Company
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Benchmarking
- 12.5.4. Recent Development
- 12.6. AstraZeneca
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Benchmarking
- 12.6.4. Recent Development
- 12.7. UCB S.A.
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Benchmarking
- 12.7.4. Recent Development
- 12.8. Merck & Co., Inc.
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Benchmarking
- 12.8.4. Recent Development
- 12.9. Boehringer Ingelheim International GmbH
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Benchmarking
- 12.9.4. Recent Development
- 12.10. Pfizer Inc.
- 12.10.1. Company Overview
- 12.10.2. Financial Performance
- 12.10.3. Product Benchmarking
- 12.10.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
